A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia

PharmacoEconomics

Volumn 11, Issue 6, 1997, Pages 550-565

  Cockrum, Paul C ^a,d   Finder, Steven F ^b   Ries, Andrea J ^c,e   Potyk, Roger P ^d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MedAnalysis   (United States)

^c Dept of Def Pharmacoeconomic Ctr ^*  (United States)

^d PFIZER INC   (United States)

^e Pharmacoeconomic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; FINASTERIDE; PRAZOSIN; TERAZOSIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION;

EID: 0030741814     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711060-00004     Document Type: Article

References (51)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline, No. 8. AHCPR Publication No. 94-0582. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, Feb 1994
2. Sagalowsky AI, Wilson JD. Hyperplasia and carcinoma of the prostate. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991: 1629-30
3. Lu-Yao GL, Barry MJ, Chang CH. Prostate Patient Outcomes Research Team (PORT), et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Urology 1994; 44: 692-8
4. McKelvie GB, Collins GN, Hehir M, et al. A study of benign prostatic hyperplasia: a challenge to British urology. Br J Urol 1993; 71: 38-42
5. Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5α-reductase inhibitors and α-adrenergic antagonists. Mayo Clin Proc 1993; 68: 670-9
6. Graversen PH, Gasser TC, Wasson JH, et al. Controversies about indications for transurethral resection of the prostate. J Urol 1989; 141: 475-81
7. Scott WG, Scott HM. Annual costs of benign prostatic hyperplasia in New Zealand. Pharmacoeconomics 1993; 4 (6): 455-68
8. Drummond MF, McGuire AJ, Black NA, et al. Economic burden of treated benign prostatic hyperplasia in the United Kingdom. Br J Urol 1993; 71: 290-6
9. Abrams PH. Detrusor instability in bladder outlet obstruction. Neurourol Urodyn 1985; 4: 317-28
10. Schlegel PN. Medical management of prostatic diseases. Adv Intern Med 1994; 39: 569-601
11. Cooner WH, Roberts RG. Prostate disease. Am Fam Physician 1994; Winter: 1-15
12. Boyarsky S, Jones G, Paulson DF, et al. A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1976; 68: 29-32
13. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 17: 1185-91
14. Jønler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994; 47: 66-81
15. Lacy C, Armstrong LL, Lipsy RJ, et al., editors. APhA drug information handbook. 1994-1995 ed. Cleveland (OH): Lexi-Comp, 1993
16. United States Pharmacopeia Dispensing Information. Drug Information for the Health Care Professional. 13th ed. Rockville (MD): United States Pharmacopeial Convention, Inc., 1993
17. Finasteride Package Insert. Merck and Co., 1994
18. Terazosin Package Insert. Abbott Laboratories, 1993
19. Prazosin Package Insert. Pfizer, 1990
20. Doxazosin Package Insert. Roerig, 1993
21. Alpha-1-Adrenergic Blockers. In: Olin BR, editor. Facts and comparisons. St. Louis (MO): Facts and Comparisons, Inc., 1994: 163j
22. Rittmaster RS. Finasteride. N Engl J Med 1994; 330: 120-5
23. Townsend RJ. Post-marketing drug research and development. Drug Intell Clin Pharm 1987; 21: 134-6
24. Bootman JL, Townsend RJ, McGahn WF. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney, 1991
25. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics 1992; 1 (1): 20-9
26. Holme JB, Christensen MM, Rasmussen PC, et al. Twenty-nine week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 1994; 28: 77-82
27. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51
28. Fabricius PG, Weizert P, Dunzendorfer U, et al. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled clinical trial. Prostate Suppl 1990; 3: 85-93
29. Lepor H, Meretyk S, Knapp-Maloney G. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J Urol 1992; 147: 1554-7
30. 1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993; 72: 822-5
31. Buzelin JM, Herbert M, Blondin P, The PRAZALF Group. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922-7
32. Moore E, Bracken B, Bremner B, et al. Proscar®: five-year experience. Eur Urol 1995; 28: 304-9
33. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
34. Ruutu ML, Hansson E, Juusela HE, et al. Efficacy and side-effects of prazosin as a symptomatic treatment of benign prostatic obstruction. Scand J Urol Nephrol 1991; 25: 15-9
35. 1 receptor blocker, in the treatment of benign prostatic hypertrophy. Curr Ther Res Exp 1990; 48: 1066-74
36. Christensen MM, Holme JB, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction, a double blind trial. Scand J Urol Nephrol 1993; 27: 39-44
37. Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995; 46: 477-83
38. Di Silverio F. Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. Br J Urol 1992; 70 (Suppl. 1): 22-6
39. Brawer MK, Adams G, Epstein H, Terazosin Benign Prostatic Hyperplasia Study Group. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993; 2: 929-35
40. Lepor H. The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia. J Androl 1991; 12: 389-94
41. American Medical Association. Physician's current procedural terminology. 4th. ed. Chicago: Americal Medical Association, 1993
42. American Medical Association. Medicare RBRVS: the physician's guide. Chicago: American Medical Association, 1993
43. Rudd P. Medication compliance: correlation with clinical outcomes. PT 1994; 19 Suppl. 4s: 10s-8s
44. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4
45. Pullar T, Birtwell AJ, Wiles PG, et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1988; 44: 540-5
46. Roehrborn CG, Oesterling JE, Auerbach S, HYCAT Investigator Group, et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-68
47. Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275-8
48. Kirby RS, Coppinger SW, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 136-42
49. Chapple CR, Stott M, Abrams PH, et al. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285-94
50. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-9
51. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.